C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.
about
A genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes, as measured by both A1C and glucoseEvaluation of Candidate Biomarkers of Type 1 Diabetes via the Core for Assay ValidationImmune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experienceDefining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus reportHeterogeneity of B Cell Functions in Stroke-Related Risk, Prevention, Injury, and RepairDisease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Type 1 diabetes: translating mechanistic observations into effective clinical outcomesImproved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial)Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR TrialUpdate and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.Serum insulin, insulin resistance, beta-cell dysfunction, and gallstone disease among type 2 diabetics in Chinese population: a community-based study in Kinmen, Taiwan.Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial.Development of the diabetes typology model for discerning Type 2 diabetes mellitus with national survey data.Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation.Approaches in type 1 diabetes research: A status report.Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): Report of the Committee of Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus.Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method.Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control.A Practical Review of C-Peptide Testing in DiabetesBanting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes.Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetesA diagnostic approach for defining idiopathic remitting diabetes: a retrospective cohort study.Distribution of C-peptide and its determinants in North American children at risk for type 1 diabetes.Immunotherapy of type 1 diabetes: where are we and where should we be going?The road not taken: a path to curing type 1 diabetes?Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetesRecommendations for the definition of clinical responder in insulin preservation studiesSample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes.Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes.Acute response of peripheral blood cell to autologous hematopoietic stem cell transplantation in type 1 diabetic patient.Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study.Gene CNVs and protein levels of complement C4A and C4B as novel biomarkers for partial disease remissions in new-onset type 1 diabetes patientsPrognostic performance of metabolic indexes in predicting onset of type 1 diabetes.Low levels of C-peptide have clinical significance for established Type 1 diabetes.β-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up.Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes.Temporal trends of HLA, CTLA-4 and PTPN22 genotype frequencies among type 1 diabetes in Continental Italy.Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.Adventures with insulin in the islets of Langerhans
P2860
P921
Q24642266-1C6D8087-75A8-4D76-ACA7-353D58036C45Q26783728-68F37ABF-3E41-427B-97CA-01C25EBEF838Q26850621-C5BC711D-D0A9-44A5-93FF-E22CABE76615Q27687598-4B95156A-235F-4B50-AD5E-C777CE9996C7Q28078211-26ED72E7-8D25-429B-A588-5A73C7C20129Q28081034-B3BFCDC1-B36C-437C-9771-821A4B4BC03DQ28287737-25651729-D362-4DBA-AB09-2247694AD619Q28731029-85CB74C8-5811-4D0E-9ACF-7E58EBB9895DQ28742007-995EF868-D974-49A9-8ED6-77423EB07266Q30392979-53E039A6-7F47-43F6-BAE6-462542E43A5BQ30393149-6BFA5DD3-8611-4B8C-ACF2-33AF3802958EQ30567434-3D6F8AD3-9717-4EB2-9039-3FBD562D9F8CQ31169714-10B99807-8223-4A14-A1F9-7FC9325A6FE8Q33344421-D2A5D810-F557-483A-8167-063503E07459Q33616086-F45B905B-301C-4006-AD50-9B5519D58C31Q33628681-C2FDC2A3-AC69-421C-B4B2-999BAA13E875Q33634067-28CF6085-6C13-4439-BD3F-5426EE32F370Q33683730-EDF3EBB1-7857-40BA-9E8E-873EC5D09716Q33732640-A1E74EBA-6411-460E-A5C3-B2B52482DAC0Q33750667-C1B018E1-F70A-4C3D-A475-7721F20772E1Q33751549-841FA734-4D49-46BA-AB2A-1A1D62D55302Q33783221-DAF64993-2FDC-445A-B39E-3DE88D672900Q33793803-B77DB8ED-6C88-4ABA-8C90-8C6AC75FD9E1Q33815506-09D83AE7-C9B2-44F4-8C01-EE730E1444EBQ33859301-2ABA3F38-7767-4F61-B1C9-0A576B148DF9Q33919957-D181F96F-AA45-458F-98BC-D8A9042E8492Q34077400-9345920E-A207-4F79-9629-829204766C18Q34079225-D0C61E47-59F0-453F-A6F2-523E54A2EDF1Q34131203-9821DD83-92FD-402E-993F-D7E14C867D63Q34182038-9A0B5091-E58F-41E3-A088-F9C73312D6B7Q34207348-D5DA3AC3-2BE1-4671-8691-375084ADC995Q34260546-3ABC4309-283B-4B46-B9B4-CCD5592083A6Q34351648-C757B167-B867-47DD-9778-48E9FA356E1CQ34484912-FFBFD3BB-5B9D-4EA8-8B4E-0A6D58D401ACQ34497677-9FAAA7FE-89C0-463D-B34E-12A4A54A4DF1Q34507037-E072C7A8-2BE7-4A2C-A156-7819C1161A41Q34583267-063856C3-E4C0-4E07-AB2C-97DEAD6967FBQ34684270-58606AD2-2DAA-4C30-B629-4B66E042C58EQ34813843-C62B2159-3D16-4EEB-94E3-649624D8F560Q34978853-7181AD7B-B0CD-4C60-B65D-7770B4D049A2
P2860
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
C-peptide is the appropriate o ...... workshop, 21-22 October 2001.
@en
C-peptide is the appropriate o ...... workshop, 21-22 October 2001.
@nl
type
label
C-peptide is the appropriate o ...... workshop, 21-22 October 2001.
@en
C-peptide is the appropriate o ...... workshop, 21-22 October 2001.
@nl
prefLabel
C-peptide is the appropriate o ...... workshop, 21-22 October 2001.
@en
C-peptide is the appropriate o ...... workshop, 21-22 October 2001.
@nl
P2093
P1433
P1476
C-peptide is the appropriate o ...... workshop, 21-22 October 2001.
@en
P2093
Carla J Greenbaum
G Alexander Fleming
Hubert Kolb
Jay S Skyler
Jerry P Palmer
Kenneth S Polonsky
Kevan C Herold
Lisa D Jansa
Michael W Steffes
Paolo Pozzilli
P2507
P304
P356
10.2337/DIABETES.53.1.250
P407
P577
2004-01-01T00:00:00Z